AIM ImmunoTech Reports Positive Mid-Year Data in Pancreatic Cancer Trial

AIM ImmunoTech has released encouraging mid-year results from its ongoing Phase II DURIPANC trial, which evaluates Ampligen (rintatolimod) in combination with AstraZeneca’s Imfinzi (durvalumab) for metastatic pancreatic cancer patients who remained stable after Folfirinox treatment. Conducted in collaboration with Erasmus Medical Center in the Netherlands, the single-centre study aims to enroll 25 participants; 14 patients have been enrolled to date.

The primary objective is to assess clinical benefit rate, with progression-free survival (PFS), overall survival (OS), and immune-monitoring as secondary endpoints. Results show a favourable safety profile, with 21% of patients experiencing PFS over six months and another 21% still progression-free. Notably, 64% of eligible patients demonstrated OS beyond six months.

Ampligen has been under investigation for pancreatic cancer since 2017, with over 50 patients treated under early access programmes. Further analysis will examine potential biomarkers and mechanistic insights, aiming to address this critical unmet need.

31-07-2025